3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
162
Myelodysplastic Syndromes
44
Leukemia, Myelomonocytic, Chronic
26
Leukemia
16
Myeloproliferative Disorders
11
Recurrence
9
Hematologic Neoplasms
8
Neoplasms
6
Lymphoma, T-Cell, Peripheral
6
Primary Myelofibrosis
5
Leukemia, Biphenotypic, Acute
5
Anemia, Refractory, with Excess of Blasts
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Leukemia, Monocytic, Acute
4
Hematologic Diseases
4
GATA2 Deficiency
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pathologic Complete Response
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma
3
Hodgkin Disease
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Polycythemia Vera
2
Lymphoma, T-Cell
2
Interventions
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ruxolitinib
1
ponatinib
1
pembrolizumab
1
ibrutinib
1
Quality of Life
1
Electrocardiography
1
Clinical Laboratory Techniques
1
CPI-0610
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Marrow Diseases
×
Azacitidine
×
1 year
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled